FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2899043357> ?p ?o ?g. }

• W2899043357 endingPage "1647" @default.
• W2899043357 startingPage "1647" @default.
• W2899043357 abstract "Abstract Introduction: Hodgkin lymphoma (HL) is a rare disease that commonly occurs in AYAs, defined in the United States as patients 15 to 39 years of age. Brentuximab vedotin (Adcetris®; A) is an anti-CD30 antibody-drug conjugate approved for adult patients with previously untreated stage III or IV classical HL (cHL) in combination with doxorubicin, vinblastine and dacarbazine (AVD) chemotherapy based on results from the phase 3 ECHELON-1 trial which demonstrated a significantly improved modified progression-free survival (mPFS) compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) (HR, 0.77; 95% CI, 0.60-0.98; P=0.04) (Connors JM, et al. N Engl J Med. 2018;378:331-344). Here we describe key efficacy and safety results for 18-to-39-year-old AYA patients enrolled in ECHELON-1. Methods: ECHELON-1 is a global, open-label, multicenter, randomized trial of patients with previously untreated stage III or IV cHL. Patients ≥18 years of age enrolled from both academic and community sites were randomized to receive A+AVD (n=664) or ABVD (n=670). The primary endpoint was mPFS, defined as progression, death, or receipt of additional anticancer therapy for patients who were not in complete response after completion of frontline therapy, as adjudicated by an independent review facility (IRF). Safety and tolerability was also assessed. To account for regional differences in the age ranges that define AYA patients, this exploratory subgroup analysis compares efficacy and key safety outcomes for AYA patients <30 and ≤39 years of age. Results: The AYA population consisted of 771 patients comprising 57.8% of the total trial population; the cohort comprised 303 patients aged 30 to 39 years, and 468 patients aged <30 years including 137 patients aged 18 to 21 years, 171 patients aged 22 to 25 years, and 160 patients aged 26 to 29 years. In patients aged <30 years, 244 received A+AVD and 224 received ABVD; in those ≤39 years of age, 396 received A+AVD and 375 received ABVD. Baseline demographics and disease characteristics were similar across age groups and treatments. The proportion of AYA patients treated in the Americas (40%), Europe (50%) and Asia (9%) reflected those of the overall trial population. Consistent with the overall trial population, median follow-up time was approximately 24 months for both age groups. AYA patients receiving A+AVD had an improved overall mPFS compared with patients receiving ABVD (≤39 years of age, HR 0.697 [95% CI, 0.495-0.980]; <30 years of age, HR 0.587 [95%CI, 0.376-0.916]) (Figure). The 2-year mPFS, also per IRF, for patients ≤39 years who received A+AVD was 84.6% vs 78.6% for those who received ABVD; patients aged <30 years receiving A+AVD also had improved 2-year mPFS compared with patients receiving ABVD (86.7% vs 74.4% respectively). Conventional PFS, as measured by investigators, was consistent with mPFS results for each age group: the HR for PFS in patients receiving A+AVD vs ABVD was 0.652 (95% CI, 0.449-0.945; P=0.023) in patients ≤39 years of age and 0.595 (95% CI, 0.367-0.965; P=0.033) in patients aged <30 years. The rate of treatment-emergent adverse events (TEAEs) in patients receiving A+AVD or ABVD was similar across age groups and reflected that of the overall trial population. TEAEs of interest include peripheral neuropathy (PN), febrile neutropenia (FN), and pulmonary-related toxicity (PRT). For patients receiving A+AVD or ABVD, any-grade PN occurred 64% and 40% of AYA patients; the majority (69%) of patients with PN had improvement/resolution of PN. The rate of FN in patients on A+AVD or ABVD arms was 16% and 5%, respectively; the incidence of FN was lower in patients who received G-CSF primary prophylaxis (9% and 5%, respectively). The incidence of PRT was low on both A+AVD (2%) and ABVD arms (4%). Conclusions : This exploratory analysis of ECHELON-1 demonstrated that AYAs receiving A+AVD had significantly improved mPFS with a manageable tolerability profile compared with AYA patients receiving ABVD. A+AVD can be considered a treatment option for AYAs with advanced-stage cHL. Additional data presented will focus on comparing results between AYA age ranges. Disclosures Crosswell: Seattle Genetics: Other: stock ownership in Seattle Genetics. LaCasce:Research to Practice: Speakers Bureau; Humanigen: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Bristol-Myers Squibb: Other: Data safety and monitoring board. Bartlett:Affimed: Research Funding; Pharmacyclics: Research Funding; Janssen: Research Funding; Bristol-Meyers Squibb: Research Funding; Merck & Co: Research Funding; KITE: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Research Funding; Novartis: Research Funding; Immune Design: Research Funding; Genentech: Research Funding; Pharmacyclics: Research Funding; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Research Funding; Novartis: Research Funding; Acerta: Membership on an entity's Board of Directors or advisory committees; Millennium: Research Funding; ImaginAB: Research Funding; Forty Seven: Research Funding. Straus:Medical Crossfire: Speakers Bureau; DAVA Oncology: Consultancy, Honoraria; InPractice Elselvier: Consultancy; JUNO: Consultancy; Bayer: Consultancy; Roch China: Speakers Bureau; Seattle Genetics: Consultancy; Memorial Sloan Kettering Cancer Center: Employment; Onco Tracker: Consultancy; Millenium (Takeda): Consultancy, Research Funding. Fenton:Seattle Genetics, Inc.: Employment, Equity Ownership. Engley:Seattle Genetics: Employment. Jolin:Takeda Pharmaceuticals International Co.: Employment. Liu:Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited: Employment. Zinzani:TG Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Bayer: Membership on an entity's Board of Directors or advisory committees; Astra Zeneca: Speakers Bureau; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; Verastem: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; SERVIER: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; PFIZER: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Honoraria, Speakers Bureau; Janssen: Honoraria, Speakers Bureau; TG Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celltrion: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Collins:Gilead: Consultancy, Honoraria, Speakers Bureau; Roche: Consultancy, Honoraria, Speakers Bureau; Amgen: Research Funding; Takeda: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Research Funding; Celleron: Consultancy, Honoraria; MSD: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria, Research Funding; Celgene Corporation: Research Funding; Pfizer: Consultancy, Honoraria. Grigg:Roche: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees." @default.
• W2899043357 created "2018-11-09" @default.
• W2899043357 creator A5006117950 @default.
• W2899043357 creator A5017873196 @default.
• W2899043357 creator A5021965002 @default.
• W2899043357 creator A5026265919 @default.
• W2899043357 creator A5038596323 @default.
• W2899043357 creator A5059055898 @default.
• W2899043357 creator A5060408501 @default.
• W2899043357 creator A5078397650 @default.
• W2899043357 creator A5085801543 @default.
• W2899043357 creator A5090559016 @default.
• W2899043357 creator A5091087783 @default.
• W2899043357 creator A5091882595 @default.
• W2899043357 date "2018-11-29" @default.
• W2899043357 modified "2023-10-16" @default.
• W2899043357 title "Brentuximab Vedotin with Chemotherapy in Adolescents and Young Adults (AYA) with Stage III or IV Hodgkin Lymphoma: A Subgroup Analysis from the Phase 3 Echelon-1 Study" @default.
• W2899043357 doi "https://doi.org/10.1182/blood-2018-99-112907" @default.
• W2899043357 hasPublicationYear "2018" @default.
• W2899043357 type Work @default.
• W2899043357 sameAs 2899043357 @default.
• W2899043357 citedByCount "4" @default.
• W2899043357 countsByYear W28990433572019 @default.
• W2899043357 countsByYear W28990433572020 @default.
• W2899043357 crossrefType "journal-article" @default.
• W2899043357 hasAuthorship W2899043357A5006117950 @default.
• W2899043357 hasAuthorship W2899043357A5017873196 @default.
• W2899043357 hasAuthorship W2899043357A5021965002 @default.
• W2899043357 hasAuthorship W2899043357A5026265919 @default.
• W2899043357 hasAuthorship W2899043357A5038596323 @default.
• W2899043357 hasAuthorship W2899043357A5059055898 @default.
• W2899043357 hasAuthorship W2899043357A5060408501 @default.
• W2899043357 hasAuthorship W2899043357A5078397650 @default.
• W2899043357 hasAuthorship W2899043357A5085801543 @default.
• W2899043357 hasAuthorship W2899043357A5090559016 @default.
• W2899043357 hasAuthorship W2899043357A5091087783 @default.
• W2899043357 hasAuthorship W2899043357A5091882595 @default.
• W2899043357 hasConcept C126322002 @default.
• W2899043357 hasConcept C143998085 @default.
• W2899043357 hasConcept C146357865 @default.
• W2899043357 hasConcept C151730666 @default.
• W2899043357 hasConcept C187960798 @default.
• W2899043357 hasConcept C205545832 @default.
• W2899043357 hasConcept C2776694085 @default.
• W2899043357 hasConcept C2778191690 @default.
• W2899043357 hasConcept C2778336483 @default.
• W2899043357 hasConcept C2779338263 @default.
• W2899043357 hasConcept C2992779791 @default.
• W2899043357 hasConcept C31760486 @default.
• W2899043357 hasConcept C44249647 @default.
• W2899043357 hasConcept C71924100 @default.
• W2899043357 hasConcept C86803240 @default.
• W2899043357 hasConceptScore W2899043357C126322002 @default.
• W2899043357 hasConceptScore W2899043357C143998085 @default.
• W2899043357 hasConceptScore W2899043357C146357865 @default.
• W2899043357 hasConceptScore W2899043357C151730666 @default.
• W2899043357 hasConceptScore W2899043357C187960798 @default.
• W2899043357 hasConceptScore W2899043357C205545832 @default.
• W2899043357 hasConceptScore W2899043357C2776694085 @default.
• W2899043357 hasConceptScore W2899043357C2778191690 @default.
• W2899043357 hasConceptScore W2899043357C2778336483 @default.
• W2899043357 hasConceptScore W2899043357C2779338263 @default.
• W2899043357 hasConceptScore W2899043357C2992779791 @default.
• W2899043357 hasConceptScore W2899043357C31760486 @default.
• W2899043357 hasConceptScore W2899043357C44249647 @default.
• W2899043357 hasConceptScore W2899043357C71924100 @default.
• W2899043357 hasConceptScore W2899043357C86803240 @default.
• W2899043357 hasIssue "Supplement 1" @default.
• W2899043357 hasLocation W28990433571 @default.
• W2899043357 hasOpenAccess W2899043357 @default.
• W2899043357 hasPrimaryLocation W28990433571 @default.
• W2899043357 hasRelatedWork W1987468340 @default.
• W2899043357 hasRelatedWork W2117200606 @default.
• W2899043357 hasRelatedWork W2335871284 @default.
• W2899043357 hasRelatedWork W2380840159 @default.
• W2899043357 hasRelatedWork W2383498641 @default.
• W2899043357 hasRelatedWork W2899043357 @default.
• W2899043357 hasRelatedWork W3177222902 @default.
• W2899043357 hasRelatedWork W4303983601 @default.
• W2899043357 hasRelatedWork W4310117708 @default.
• W2899043357 hasRelatedWork W2806497351 @default.
• W2899043357 hasVolume "132" @default.
• W2899043357 isParatext "false" @default.
• W2899043357 isRetracted "false" @default.
• W2899043357 magId "2899043357" @default.
• W2899043357 workType "article" @default.